TCH (chemotherapy)

TCH (chemotherapy)

TCH is a chemotherapy regimen used for the treatment of breast cancer. It is an acronym for the drugs used in the regimen: Docetaxel, Carboplatin, and Trastuzumab.

Overview

TCH chemotherapy is a combination of three drugs: Docetaxel, Carboplatin, and Trastuzumab. This regimen is typically used to treat HER2-positive breast cancer, a subtype of breast cancer that tests positive for a protein called human epidermal growth factor receptor 2 (HER2). HER2 promotes the growth of cancer cells, and HER2-positive breast cancers tend to be more aggressive than other types of breast cancer.

Components

Docetaxel

Docetaxel is a chemotherapy drug used in the treatment of various types of cancer, including breast cancer, lung cancer, prostate cancer, and stomach cancer. It works by interfering with the growth and spread of cancer cells in the body.

Carboplatin

Carboplatin is a chemotherapy drug used to treat various types of cancer, including ovarian cancer, lung cancer, and head and neck cancer. It works by interfering with the DNA in cancer cells, preventing them from dividing and growing.

Trastuzumab

Trastuzumab is a targeted therapy drug used in the treatment of HER2-positive breast cancer. It works by attaching to the HER2 proteins on cancer cells, blocking them from receiving growth signals.

Side Effects

Like all chemotherapy regimens, TCH has potential side effects. These can include nausea, vomiting, hair loss, fatigue, and a low white blood cell count, which can lead to an increased risk of infection.

See Also

• Chemotherapy
• Breast cancer
• HER2-positive breast cancer
• Docetaxel
• Carboplatin
• Trastuzumab

TCH (chemotherapy) Resources
Latest articles Most recent articles Ongoing trials	Wikipedia